EP
SLDB icon

Essential Partners’s Solid Biosciences SLDB Stock Holding History

Essential Partners’s Portfolio SLDB Stock Details SLDB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.63K Sell
263
-2,767
-91% -$21K ﹤0.01% 1860
2026
Q1 		$21.8K Buy
3,030
+2,767
+1,052% +$17.8K 0.01% 894
2025
Q4 		$1.48K Hold
263
– – ﹤0.01% 1903
2025
Q3 		$1.62K Hold
263
– – ﹤0.01% 1860
2025
Q2 		$1.28K Buy
+263
New +$930 ﹤0.01% 1447

Other funds holding SLDB

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Essential Partners's SLDB Position: Q2 2026 in Review

Essential Partners reduced its Solid Biosciences (SLDB) stake by 91% in Q2 2026, selling an estimated $21K and leaving 263 shares worth $2.63K. The position accounts for ﹤0.01% of the portfolio, ranked #1860.

Essential Partners first reported a position in SLDB in Q2 2025 and has held it in 5 quarters since. The position peaked at $21.8K in Q1 2026. 157 funds tracked by Wall St. Rank hold SLDB as of Q2 2026.

  • Essential Partners held 263 shares of Solid Biosciences worth $2.63K as of Q2 2026.
  • Essential Partners sold 2,767 Solid Biosciences shares in Q2 2026, an estimated $21K.
  • Solid Biosciences made up ﹤0.01% of Essential Partners's portfolio in Q2 2026, its #1860 holding.
  • Essential Partners first reported a position in Solid Biosciences in Q2 2025 and has held it in 5 quarters since.
  • Essential Partners's Solid Biosciences position peaked at $21.8K in Q1 2026.
  • 157 funds tracked by Wall St. Rank held Solid Biosciences as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.